Related Experiment Videos
[Antiplatelet effect of clopidogrel]
S Uchiyama1, M Yamazaki, S Maruyama
1Department of Neurology, Tokyo Women's Medical College.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|February 1, 1992
Summary
Clopidogrel, a thieno-pyridine derivative, potently inhibits platelet aggregation and prolongs bleeding time, offering an effective antiplatelet therapy. It is well-tolerated and expected to reduce neutropenia risk in atherosclerosis patients.
Area of Science:
- Pharmacology
- Hematology
- Cardiovascular Medicine
Background:
- Clopidogrel is a novel thieno-pyridine derivative.
- It exhibits potent inhibition of adenosine diphosphate (ADP)-induced platelet aggregation.
- This action is more effective than ticlopidine.
Purpose of the Study:
- To evaluate the antiplatelet effects of clopidogrel.
- To compare its efficacy and safety with ticlopidine.
- To assess its potential in preventing thrombosis in atherosclerosis patients.
Main Methods:
- Phase I clinical study in Japan.
- Administration of clopidogrel at doses of 25, 50, and 75 mg.
- Measurement of ADP-induced platelet aggregation and bleeding time.
- Evaluation in experimental animal models for antithrombotic effects.
Main Results:
- Significant inhibition of ADP-induced platelet aggregation observed.
- Prolongation of bleeding time noted at tested doses.
- Effects were comparable to 200-300 mg of ticlopidine.
- Demonstrated antithrombotic effects in animal models.
Conclusions:
- Clopidogrel is a potent antiplatelet agent.
- It is well-tolerated in patients with atherosclerosis at risk of thrombosis.
- Lower doses may reduce the incidence of neutropenia compared to ticlopidine.